A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Exclusion Criteria

• •Known hypersensitivity to AC-076 or drugs of the same class, or any of their excipients
• •Family or personal history of prolonged bleeding or bleeding disorders, intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers
• •Platelet count \< 120 × 109 L-1 at screening
• •Known platelet disorders
• •Orthostatic hypotension at screening (i.e., decrease from supine to standing BP of \> 20 mmHg in SBP or \> 10 mmHg in DBP after being in standing position for 3 min)
• •Previous treatment with acetylsalicylate, non-steroidal anti-inflammatory drugs or any medication with blood thinning activity within 3 weeks prior to study drug administration; or with any other prescribed medications (including vaccines) or over the counter medications within 2 weeks prior to study drug administration
• •Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol